ISTH 2023 Supported Symposia & Presentation Theaters
 

​

The following companies will organize supported symposia and/or presentation theater sessions at the ISTH 2023 Congress in Montréal, showcasing the latest scientific, diagnostic and therapeutic advances in thrombosis and hemostasis. 

​

See below for session titles, dates and times.

​

Saturday, June 24, 11:30 - 12:45 Supported Symposia

• Current Advanced in Deficient Factors, Heparin Testing and HIL (HORIBA Medical)
  Room 516

• Current and Future Strategies in Managing DOAC Reversal in Urgent Surgery (Norgine)
  Room 510

• Leading the Change in Hemophilia A: Guidance on Enhancing Prophylactic Care With Innovative EHL FVIII Products (This activity is provided by PVI, PeerView Institute for Medical Education, and supported by an educational grant from Sanofi.)
  Room 710A

• ITP: More Than Just a Low Platelet Disorder (Sanofi)
  Room 520

• ELEVATE, EXTEND, EXPLORE: Raising the Bar for Your Patients with Haemophilia A (Sobi TM)
  Room 511

​

Sunday, June 25, 7:00 - 7:45 Supported Symposia

• Improving the Effectiveness of Anticoagulant Therapy: The Promise of Factor XI Inhibition (Anthos Therapeutics)
  Room 511

• Recognizing Thrombotic Risk in Patients with AIHA: Opportunities and Challenges (Sanofi - Global Scientific Communications Rare Blood Disorders)
  Room 520

​

Sunday, June 25, 12:15 - 13:00 Presentation Theaters

• Treating the Next Generation: How Far Have We Come in Haemophilia A? (F. Hoffman - La Roche LTD)
  Presentation Theater 1

• Bringing Breakthrough Innovation in Haemophilia B with Inhibitors (Novo Nordisk Healthcare AG)
  Presentation Theater 4

• Breaking the Boundaries of Haemostasis Testing With the CN-Series: Optimising Haemostasis Testing to Provide Greater Diagnostic Value and Enhanced Quality of Results (Sysmex)
  Presentation Theater 2

• Rapid HIT Testing:  Are Two Tests Better Than One? (Werfen)
  Presentation Theater 3 

​

Sunday, June 25, 13:15 - 14:30 Supported Symposia

• Gene Therapy: Navigating Unfamiliar Territory in Hemophilia (BioMarin)
  Room 510

• From Risk Assessment to Treatment Selection: Improving Cancer-Associated Thrombosis Outcomes (Bristol Myers Squibb/Pfizer)
  Room 520

• Etranacogene Dezaparvovec: From Promise to Practice (CSL Behring)
  Room 511

• Maintaining Hemostasis in Women: Breakthroughs and Ongoing Challenges (Supported by an educational grant from Haemonetics Corporation)
  Room 513

• Achieving Higher Factor VIII Levels in Hemophilia A (Sanofi)
  Room 516

• From Guidelines to Practice: Expert Insights on Clinical Management of Hemostatic and Thrombotic Emergencies (Takeda Pharmaceutical Company Limited)
  Room 524

​

Monday, June 26, 7:00 - 7:45 Supported Symposium

• Can We Balance the Thrombosis and Bleeding Risk in Contemporary Anticoagulation? (Sanofi)
  Room 510

​

Monday, June 26, 12:15 - 13:00 Presentation Theaters

• ROCTAVIAN®: Unlocking the Potential of Gene Therapy for Hemophilia A (BioMarin)
  Presentation Theater 1

• Building Confidence Using HEMLIBRA Through Best-Practice Sharing – A Practical Discussion (F. Hoffmann-La Roche Ltd.)
  Presentation Theater 2

• More Ambitious Prophylaxis for all Haemophilia B Patients: WHY and HOW? (Novo Nordisk Healthcare AG)
  Presentation Theater 3

• Finding the Trusted Factor: 9 Years of Real-World Experience with EHL FIX Therapy (Sanofi and Sobi)
  Presentation Theater 4

​

Monday, June 26, 13:15 - 14:30 Supported Symposia

• Addressing the Challenge of Inhibitors: A New Era in Non-Factor Replacement Therapy (Novo Nordisk Healthcare AG)
  Room 516

• Final Results of the WIL-31 Study – Should Prophylaxis be the New Treatment Standard for von Willebrand Disease Patients With Severe Bleeding? (Octapharma)
  Room 511

• Innovative Disruption in Hemophilia and the Aspiration of Zero Bleeds (Pfizer)
  Room 510

• Current Unmet Needs of People Living with Hemophilia: Can Emerging Therapies Address These Needs? (Sanofi)
  Room 520

• Breaking Free: Pushing Boundaries in Haemophilia A (Sobi TM)
  Room 513

• A Debate: Congenital TTP - Should Prophylaxis be Recommended for All? (Takeda Pharmaceutical Company Limited)
  Room 710A

​

Tuesday, June 27, 12:15 - 13:00 Presentation Theaters

• Hereditary Factor X Deficiency in America Survey – Summary of Results (Kedrion Biopharma)
  Presentation Theater 1

• Long-term Experience with Ryplazim: Data from Expanded Access Programs (Kedrion Biopharma)
  Presentation Theater 4

• sthemO Systems: the Optimal Solution for Your Hemostasis Laboratory (Stago)
  Presentation Theater 2

• A New Dawn in Factor VIII Inhibitor Testing (Technoclone)
  Presentation Theater 3

​

Tuesday, June 27, 13:15 - 14:30 Supported Symposia

• Keeping It Real: Reversing Effects of Anticoagulation in the Modern Era with Real-World Data (AstraZeneca)
  Room 710A

• Answering the Diversity of Haemophilia: Navigating Treatment Individualisation and Shared Decision-Making (Novo Nordisk Healthcare AG)
  Room 513

• Bringing Together Two Worlds – Scientific and Clinical Insights for All-round Bleed Protection in Hemophilia A (Octapharma)
  Room 511

• Changing Lives: The Evolution of Care for iTTP (Sanofi - Global Scientific Communications Rare Blood Disorder) Room 520

• Shared Decision-Making for Gene Therapy in Hemophilia (Spark Therapeutics)
  Room 510

• Personalized Care for Von Willebrand Disease in the Real World: One Size Doesn’t Fit All (Takeda Pharmaceutical Company Limited)
  Room 516

​​